A client with advanced chronic kidney disease takes calcium acetate for hyperphosphatemia. Repeated laboratory results show calcium 11.2 mg/dL and phosphorus 6.1 mg/dL. Which action should the nurse anticipate?
1Clarify continued calcium acetate use and anticipate a non-calcium phosphate binder plan.✓ Correct answer
2Increase calcium acetate with each meal until both calcium and phosphorus rise further.
3Administer intravenous calcium gluconate to treat the elevated calcium concentration.
4Add a calcium supplement between meals without reassessing the phosphate binder.
Explanation
Calcium acetate lowers phosphorus but adds calcium. In adults with CKD receiving phosphate-lowering treatment, KDIGO recommends restricting calcium-based phosphate binders, and hypercalcemia strengthens the need to reassess calcium loading. The nurse should clarify continued calcium acetate therapy and anticipate a prescriber-directed non-calcium binder strategy, such as sevelamer, while calcium, phosphorus, and PTH are evaluated together. Additional calcium would worsen hypercalcemia.
Clinical reasoning The client has persistent hyperphosphatemia plus hypercalcemia while receiving a calcium-containing binder. Increasing calcium exposure can worsen positive calcium balance and calcification risk.
Decision rule Reassess a calcium-based phosphate binder when calcium is elevated and coordinate a lower-calcium phosphate-control plan rather than adding more calcium.
Scenario 70-year-old female CKD on calcium acetate phosphate binder. New Ca 11.5·constipation. PTH stable.
Calcium-based phosphate binder — A medication such as calcium acetate that binds dietary phosphate in the gut but can contribute to calcium loading and hypercalcemia.
Non-calcium phosphate binder — A phosphate-lowering agent such as sevelamer that does not add calcium and may be selected when calcium loading is a concern.
Vascular calcification — Cardiovascular complication of CKD-MBD; lowered with non-calcium binders.